Abstract
No public abstract is available from the verified source records.
B. Davido, P. Loubet
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Dexamethasone in Hospitalized Patients with Covid-19
10.1056/nejmoa2021436 · 2021
Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis
10.1016/j.eclinm.2025.103315 · 2025
Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen
10.1016/s2666-5247(23)00139-8 · 2023
Longitudinal observation of viral load in patients infected with Omicron variant and its relationship with clinical symptoms
10.3389/fmicb.2022.1037733 · 2023
The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs
10.1093/cid/ciad582 · 2024
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
10.1080/07853890.2022.2133162 · 2022
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults
10.1093/cid/ciaf680 · 2026
Unresolved referenced work
2024
ESCMID COVID-19 living guidelines: drug treatment and clinical management
10.1016/j.cmi.2021.11.007 · 2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
10.1056/nejmoa2118542 · 2022
Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
2023
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study
10.1080/07853890.2024.2313062 · 2024
Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
10.2147/idr.s445826 · 2024
Early Versus Delayed Usage of Paxlovid in Severe Omicron-Infected Patients With Hypoxemia: A Prospective Multiple-Center Cohort Study
10.1002/hsr2.70177 · 2024
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset
10.1164/rccm.202308-1438oc · 2024
Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study
2025
Real-World Effectiveness of Nirmatrelvir/Ritonavir and Dexamethasone Among Hospitalized Patients with COVID-19: A Prospective Cohort Study
10.2147/idr.s419373 · 2023
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
10.1016/s1473-3099(25)00093-3 · 2025
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
2023
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
10.1093/cid/ciae202 · 2024
No additional external references are available.